Jorge Martinalbo

Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties

Caridad Pontes, J.M. Fontanet, Roser Vives et al. · Orphanet Journal of Rare Diseases · 2018 · 61 citations · Full text

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Mariana Chávez‐MacGregor et al. · Annals of Oncology · 2022 · 57 citations · Full text

Endocrine Oncology, Vs Physician Choice, Advanced/metastatic Breast Cancer +11

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 52 citations · Full text

CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape

Nayan Chaudhary, Alejandro Chibly, Ann Collier et al. · npj Breast Cancer · 2024 · 24 citations · Full text

On the edge of new technologies (advanced therapies, nanomedicines)

Spiros Vamvakas, Jorge Martinalbo, Ruben Pita et al. · Drug Discovery Today Technologies · 2011 · 13 citations

Nanoparticles, Nanomedicine, New Technologies +6